AVTX Avalo Therapeutics, Inc. Insider Trading

Chief Legal Officer of unprofitable biotech executes large mixed-direction trades: substantial purchases and sales totaling $1.5M on same day near 52-week highs.

Paul Varki, Avalo Therapeutics' Chief Legal Officer, executed a complex set of simultaneous buy and sell transactions totaling approximately $1.5 million—a significant portfolio activity for a C-suite officer. The timing is noteworthy: these trades occurred with the stock trading at its 52-week high after a sharp rally over recent months, not during a pullback where insider buying typically signals conviction. The company remains unprofitable with losses continuing, making this a high-risk environment where insider behavior is particularly illuminating. The mixed transaction pattern—buying while simultaneously selling at higher prices—suggests portfolio rebalancing or liquidity management rather than unambiguous conviction in the company's direction. For a CLO navigating regulatory and legal complexities at a cash-burning biotech, this activity warrants close attention to understand whether the net effect reflects confidence in turnaround prospects or prudent de-risking at an inflated valuation.

CFO Sullivan Christopher Ryan sells nearly all holdings (5 tranches) while acquiring new shares in single transaction—net liquidation despite purchase.

Sullivan Christopher Ryan, the company's CFO, executed a complex set of trades on the same day: purchasing a large block of new shares while simultaneously selling nearly his entire existing position across five separate transactions. The net effect is a substantial reduction in total ownership despite the acquisition activity. This mixed transaction pattern occurred while the stock was trading at its 52-week high and has recently rallied sharply, which typically marks a natural exit point for insiders. The company remains unprofitable and faces structural financial headwinds, making the timing of this sale—at peak valuation—particularly notable. The magnitude of selling (roughly three times the purchase value) suggests the CFO is using the strength in the stock price to trim exposure rather than build conviction in a turnaround.

CMO Doyle Mittie executes net sale of shares as stock reaches 52-week high, mixed purchase and sale activity across two trading days.

Doyle Mittie, Chief Medical Officer of Avalo Therapeutics, executed a series of paired purchases and sales across May 5–6, with total sales slightly exceeding total purchases, resulting in a net reduction of his holdings. The transactions occurred as the stock reached its 52-week peak, suggesting he took advantage of elevated valuations to trim his position. Notably, while the CMO added significantly to his holdings through purchases on May 6, he simultaneously liquidated a larger dollar value through a cascade of sales across multiple price levels on the same day, indicating a tactical rebalancing rather than unidirectional conviction. The company's financial fundamentals remain challenged—operating at a substantial loss with highly negative earnings—which provides context for why an executive might elect to de-risk his position even as the stock has appreciated sharply. Without track record or prior transaction history provided, this appears to be a prudent tactical exit for a C-suite officer: the stock is now at its highest point, and the insider chose that window to reduce exposure.

Director Almenoff buys 1,000 shares at blended avg $12.75 on AVTX amid -89.3% annual revenue decline

Director June Sherie Almenoff made 2 separate purchases totaling 1,000 shares for $12,749.50 on consecutive days (November 12–13, 2024) at prices of $12.50 and $13.00 per share. This marks her first holdings in the company, establishing a 1,000-share position. The timing coincides with a 30-day price surge of +39.1% and a 90-day gain of +48.6%, yet the stock remains -43.2% below its 52-week high of $23.74. The fundamental backdrop is stark: annual revenue contracted by -89.3%, the company posted a full-year net loss, and latest quarterly revenue was only $249,000.00—indicating a severely distressed financial profile. The purchase at $12.75 blended price occurs in a deeply challenged operational environment, not at a recovery inflection point supported by earnings or revenue stabilization.